HomeHealthAstraZeneca setups Clinical Data and Insights division in Bengaluru

AstraZeneca setups Clinical Data and Insights division in Bengaluru

Reader's Pick

AstraZeneca India Private Limited, the Global Capability Centre (GCC) of AstraZeneca, a leading science-led biopharmaceutical company, has launched a clinical data and insights division in India to further strengthen its global presence, and for the management of data-related aspects of its clinical trials. 

The Clinical Data & Insights team in Bengaluru, India, is a critical advancement to support a growing global portfolio, and build on internal data expertise. With the center starting its operations recently, the team will continue to expand by sourcing the right talent and resources for future needs.

Reporting into Development Operations in Biopharmaceuticals R&D, the Clinical Data & Insights (CDI) team is responsible for the management of data-related aspects of AstraZeneca’s clinical trials, excluding analysis and reporting. 

CDI division works across therapy areas and portfolios, supporting early and late-stage clinical programs from Phase 1 to Phase 3 with an integrated end-to-end approach for clinical data, analytics, insights, and risk management. 

- Advertisement -

Currently a 30-member team, the division is expected to grow to a 100+ member strong team by 2022.

Commenting on the launch of the CDI division in India, Siva Padmanabhan, Managing Director, AstraZeneca India Private Limited, said, “The role of GCCs in the overall growth of the parent organization is witnessing a shift. Over the last decade, GCCs in India are undertaking more strategic and transformative work critical to the success of the organization.”

“India has seen a constant uptick in investment in areas such as Business Services, Engineering, Digital, IT, R&D and Product Development from global Fortune-500 companies. AstraZeneca in India is no different – since its inception, AZIPL has supported the global organization with various services spanning IT, Business Services, and R&D from our centers in Chennai and Bengaluru, transformative projects. AstraZeneca’s decision to set up the CDI division in India is only a natural progression of this, to further capitalize on the extensive talent pool in the country,” he added.

AstraZeneca CDI’s current footprint includes over 400 employees and approximately 700 data management professionals in vendor partnerships across six countries. They are now embedding data science and Artificial Intelligence (AI) across R&D centers to enable their data teams to push the boundaries of science to deliver life-changing medicines.

- Advertisement -

Commenting on setting up a CDI division in India, Natalie Fishburn, Vice President, Global Head of Clinical Data & Insights, AstraZeneca, said, “Clinical data and insight solutions enable pharmaceutical organizations such as ours to gain in-depth visibility into the patient’s journey by extracting actionable insights from disparate data sources. The establishment of the CDI division in India is key to our strategic vision of being industry leaders in this space.” 

“How we manage data is evolving, and we are growing and expanding our capabilities to be ready for the future. In addition, the fact that the Indian market has grown significantly by offering a large talent pool, many of whom have over 10 years of experience, has further motivated us to set up this division in India,” Natalie added


Stay on top of Budget 2023 with our newsletter

We don’t spam! Read our privacy policy for more info.

- Advertisement -

Read latest Business News and Startup news on TechGraph. Watch live and latest news on TechGraph TV. Follow us on Facebook or follow us on Twitter and Instagram. Listen audio news from TechGraph Briefings on Spotify, Google Podcast, Amazon Music & on Apple Podcast.

Krishna Mali
Krishna Mali
Founder & Editor of TechGraph.

Latest News

Promoted Links

Related Stories

Sino-US trade war offers Europe’s chance to bank more Chinese reserves: Analysis

Should European countries want the euro to replace the dollar as the world's do...

Japan approves 26 trillion yen as economic stimulus package to combat overseas risks

Japan's cabinet approved an economic stimulus package worth 26 trillion yen ($2...

1Win App: Review India Apk for Android and iOS

The company 1Win has been successfully operating in the markets of many countri...

Employees union seeks FIR against Jet Airways boss Naresh Goyal, Vinay Dube and on SBI Chairman

The employee union of Jet Airways, which is facing its worst crisis, Friday sou...

Samsung Electronics asks its shareholders to use electronic voting for upcoming AGM

Technology giant Samsung Electronics has adopted electronic voting for the firs...

Rahul Gandhi hits on RCEP says, ‘Make in India’ has become ‘Buy from China’

Asserting that "Make in India" has become "Buy from China," Congress leader Rah...

NASA astronauts to carry first ever all-female spacewalk on 29 March

Two NASA astronauts are scheduled to carry out the first ever all-female spacew...

Budget 2023 Should Fouse On Increasing Research Grants to Promote Innovation in Ayurveda: Ameve Sharma of Kapiva

As the Union Finance Minister Nirmala Sitharaman, is all set to present the Ind...

News Briefings: Skillsoft opens in NYSE, Health Startups raises $1 mn, Droom crosses Rs 1000 cr GMV & More

Headlines: Power Gummies raises 1 million dollars from 9Unicorns, Droom crosses...

Budget 2023: “Govt Should Encourage Banks to Increase Funding for NBFCs,” says Parry Singh of Red Fort Capital

As the Union Finance Minister Nirmala Sitharaman, is all set to present the Ind...